Clinical Research
Predictors of Early, Late, and Very Late Stent Thrombosis After Primary Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction

https://doi.org/10.1016/j.jcin.2012.06.013Get rights and content
Under an Elsevier user license
open archive

Objectives

The purpose of this study was to evaluate the frequency and predictors of stent thrombosis (ST) after stenting for ST-segment elevation myocardial infarction (STEMI).

Background

Stent thrombosis remains a major concern with STEMI patients treated with primary percutaneous coronary intervention.

Methods

Consecutive patients (N = 1,640) undergoing stenting for STEMI were prospectively enrolled in our database and followed for 1 to 15 years. Bare-metal stents were implanted from 1995 to 2002, and drug-eluting and bare-metal stents were implanted from 2003 to 2009. Stent thrombosis was defined as definite or probable.

Results

Our population had a high risk profile, including a high incidence of Killip class III to IV (11.5%) and STEMI due to ST (10.2%). Stent thrombosis occurred in 124 patients, including 42 with early ST (0 to 30 days), 35 with late ST (31 days to 1 year), and 47 with very late ST (>1 year). The frequency of ST was 2.7% at 30 days, 5.2% at 1 year, and 8.3% at 5 years. Independent predictors of early or late ST were STEMI due to ST (hazard ratio [HR]: 4.38, 95% confidence interval [CI]: 2.27 to 8.45), small stent size (HR: 2.44, 95% CI: 1.49 to 4.00), Killip class III to IV (HR: 2.39, 95% CI: 1.30 to 4.40), and reperfusion time ≤2 h (HR: 2.09, 95% CI: 1.03 to 4.24). Drug-eluting stent was the only independent predictor of very late ST (HR: 3.73, 95% CI: 1.81 to 7.88).

Conclusions

Stent thrombosis after primary percutaneous coronary intervention is relatively frequent and continues to increase out to 5 years. New strategies are needed to prevent ST in STEMI patients, and targeted therapies are needed in patients identified at highest risk.

Key Words

predictors stent thrombosis
primary PCI
STEMI
stent thrombosis

Abbreviations and Acronyms

BMS
bare-metal stent(s)
CI
confidence interval
DES
drug-eluting stent(s)
GPI
glycoprotein IIb/IIIa platelet inhibitor
HR
hazard ratio
MI
myocardial infarction
PCI
percutaneous coronary intervention
PES
paclitaxel-eluting stent(s)
RT
reperfusion time
ST
stent thrombosis
STEMI
ST-segment elevation myocardial infarction

Cited by (0)

This study was supported by an unrestricted grant from the LeBauer Charitable Research Foundation and by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01ES045005). Dr. Brodie has served on the Speakers' Bureau for the Medicines Company and Medrad/Possis. Dr. Stuckey has served as consultant to and on the Speakers' Bureau and on the Advisory Board for Boston Scientific Corporation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.